tbuckley/cabot-search huggingface dataset:
Effect of omalizumab on angioedema in H<sub>1</sub>‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐<scp>ACT</scp>, a randomized controlled trial
Authors: P. Staubach, M. Metz, N. Chapman‐Rothe, C. Sieder, M. Bräutigam, J. Canvin, M. Maurer
Journal: Allergy (2016)

Chronic spontaneous urticaria (CSU) severely impacts quality of life (QoL), especially in patients with wheals and angioedema. Omalizumab is approved as add-on therapy for CSU patients; however, its effect on patients who are double-positive for wheals and angioedema has not been systematically studied.The primary objective was to evaluate the efficacy of omalizumab vs placebo at week 28 using the Chronic Urticaria Quality of Life (CU-Q2oL) questionnaire. Number of angioedema-burdened days, time interval between successive angioedema episodes, disease activity, angioedema-specific and overall QoL impairment were secondary objectives.X-ACT was a phase III, randomized, double-blind study conducted in 24 centres (Germany), which selectively included CSU patients with angioedema and wheals. Patients were randomized (1 : 1) to omalizumab 300 mg or placebo (every 4 weeks up to week 24) (ClinicalTrials.gov number: NCT01723072).Of the 91 patients randomized to omalizumab (n = 44) or placebo (n = 47) at baseline, 68 completed the 28-week treatment phase (omalizumab, 35; placebo, 33). Omalizumab was superior to placebo in improving CU-Q2oL scores at week 28 (P < 0.001). There was a threefold improvement in angioedema-burdened days/week with omalizumab (0.3) vs placebo (1.1). The median time to first recurrence of angioedema was 57-63 days with omalizumab and <5 days with placebo. Omalizumab significantly improved angioedema-specific QoL (P < 0.001). The adverse events reported are in line with the established safety profile of omalizumab.Omalizumab was an effective treatment option for patients with moderate-to-severe CSU symptoms and angioedema unresponsive to high doses of antihistamine treatment.
Morphologic Changes Associated with Sulfonylurea Therapy
Authors: J M BLOODWORTH
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Augmentation of Antitumor Immune Response by Trinitrophenyl (TNP)-Reactive Helper T-Cells: Enhanced Induction of Tumor-Specific Lyt-1&lt;sup&gt;+&lt;/sup&gt;2&lt;sup&gt;−&lt;/sup&gt; T-Cell-Mediated Delayed-Type Hypersensitivity From Spleen Cells of Tumor-Bearing Mice by TNP Helpers&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: T Suda, H Fujiwara, Y Mizushima, G M Shearer, T Hamaoka
Journal: JNCI Journal of the National Cancer Institute (1986)

Spleen cells from X5563 tumor-bearing syngeneic C3H/HeN mice were stimulated in vitro with trinitrophenyl (TNP)-modified or unmodified X5563 tumor cells. TNP-reactive helper T-cells obtained from TNP-primed C3H/HeN mice were added to the above cultures in an attempt to augment the induction of anti-X5563 delayed-type hypersensitivity (DTH) responses. The DTH responses were measured by adoptive transfer of cultured cells together with unmodified X5563 cells into footpads of syngeneic mice. Cultures of spleen cells from tumor-bearing mice plus X5563 or TNP-modified X5563 cells failed to generate anti-X5563 DTH responses. In contrast, addition of TNP-helper T-cells to the cultures resulted in appreciable DTH as well as in cytotoxic responses to X5563 tumor cells. Demonstration of this immunity was dependent on the presence of TNP-X5563 tumor cells as stimulators during the culture period. The anti-X5563 DTH effector cells augmented by TNP helpers were found to be of the Lyt-1+2- phenotype and were tumor specific, since DTH responses were observed when the cultured cells were injected with X5563 but not when injected with another syngeneic tumor. These results demonstrate that TNP-helper T-cells are capable of augmenting the induction of tumor-specific Lyt-1+2- T-cell-mediated DTH responses from lymphoid cells of tumor-bearing mice upon the stimulation of TNP-reactive tumor cells. The results are discussed in relation to: a previously described tumor-specific immunotherapy model in which a growing tumor regressed by virtue of TNP helpers and the implications of augmenting induction of tumor-specific DTH responses in antitumor resistance.
Meldonium use by athletes at the Baku 2015 European Games
Authors: Mark Stuart, Christian Schneider, Klaus Steinbach
Journal: British Journal of Sports Medicine (2016)

Background The aim of this report was to estimate the prevalence of meldonium use in athletes competing in the Baku 2015 European Games to contribute to the surveillance of substances on the 2015 World Anti-Doping Agency (WADA) Monitoring Program. Meldonium is reported to be used by athletes to potentially enhance personal performance and shorten the recovery period after physical activity. Methods Three sources of data were reviewed to determine the prevalence of meldonium use during the Games including: (1) athlete self-reported declarations of drug and supplement use; (2) declarations from National Olympic Committee medical teams of the list of medicines that they imported into Azerbaijan as part of their stock of drugs for administration; (3) results from the antidoping laboratories reporting the detection of meldonium. Results Meldonium was declared as imported into Azerbaijan by 2 of 50 National Olympic Committee medical teams at the Games, but athletes from 6 countries declared the use of meldonium. Only 23 of the 662 (3.5%) athletes tested from 8 to 28 June 2015 declared the personal use of meldonium, which included 13 competition winners. However, 66 of the total 762 (8.7%) athlete urine samples analysed during the Games and during precompetition tested positive for meldonium. Meldonium use was detected in athletes competing in 15 of the 21 sports during the Games. Conclusions This study highlights the widespread and inappropriate use and prescribing of this prescription drug in a generally healthy athlete population. Subsequent to these findings, WADA has included meldonium as a prohibited substance on the 2016 List of Prohibited Substances.
Studies on Lymphatic Metastasis. I. Primary Immunoregulatory Role of Regional Lymph Nodes in the Establishment of Lymphatic Metastases&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: K Yoshida, T Tachibana
Journal: JNCI Journal of the National Cancer Institute (1985)

The growth of syngeneic ascites MM48 tumor cells implanted in a hind footpad of a C3H/He mouse slowed at 10-12 days after tumor implantation. At that time, no killer activity was detected in all lymphoid organs examined, including regional lymph node. However, positive immunoregulatory activity, i.e., killer-augmenting activity, which was assessed by cytotoxicity assay with tumor-specific immune cytotoxic T-cells, was detected primarily in the regional lymph node. In contrast, local preimmunization with larger doses of irradiated tumor cells enhanced growth of subsequently challenged tumor and lymphatic metastasis. In the regional node of preimmunized tumor bearer, negative immunoregulatory activity, i.e., killer-suppressing activity, was induced. Both immunoregulatory activities were tumor specific and resided in Lyt-1+ T-cells. Tumor-specific immunoregulatory activity seemed to be related to tumor dose used for challenge, whether positive or negative immunoregulatory activity was induced. Lymphatic metastases examined by bioassay and histologic examination were evaluated with reference to immunoregulatory activity that appeared in the regional lymph node during tumor development. The incidence of tumor detection in the node by bioassay was decreased when killer-augmenting activity was present there. Proliferation of metastatic tumor cells judged by microscopic observation was in parallel with suppressor activity generated in the node.
Abstract 18100: Intertechnique Differences for Measurements of Left Volume and Ejection Fraction Between Two-dimensional Echocardiography and Real Time Three-dimensional Echocardiography Using Single Beat Full-volume Acquisition in Patients with Regional Wall Motion Abnormality
Authors: Sung-Ai Kim, Sang-Ho Jo, Hyun-Sook Kim, Sang-Jin Han, Woo-Jung Park, Chong-Yun Rhim
Journal: Circulation (2012)

Introduction: Conventional two-dimensional echocardiography (2DE) for assessment of left ventricular (LV) volume and systolic function are dependent on geometric assumptions of LV shape and at risk...
Oral Contraceptive Patient Information
Authors: Lawrence Fleckenstein
Journal: JAMA (1976)

A questionnaire was designed to assess attitudes, knowledge, and views and sources of drug information on oral contraceptives, with particular attention to the role of the patient-oriented package insert. An analysis of 828 completed questionnaires shows that many women are apprehensive about the safety of oral contraceptives. The impact of the patient-oriented oral contraceptive insert on the women surveyed appears to be positive. The present labeling is read and found useful by most oral-contraceptive users. Patients were variably informed about the correct use and side effects discussed in current labeling, suggesting a need for improved transmission of important drug information. Patients preferred information from health professionals and printed sources over media sources. Balanced label information about risks of oral contraceptives should be made available to improve the likelihood of sound risk-benefit judgments. (<i>JAMA</i>235:1331-1336, 1976)
Abstract 13062: Notch1 Signaling Regulates Adipogenesis in vivo
Authors: Motoharu Hayashi, Kyousuke Takeshita, Toyoaki Murohara
Journal: Circulation (2013)

Among four homologous Notch receptors, the Notch1 signaling is known to regulate neurogenesis and angiogenesis in the developmental stages. But its role in adipogenesis is unknown. In this study, w...
Potential prevention and treatment of oxaliplatin associated peripheral neuropathy
Authors: K. R. Hoffman
Journal: Journal of Clinical Oncology (2004)

8093 Background: The major toxicities of oxaliplatin are two different types of peripheral neuropathies, a reversible one related to the drug's infusion and an irreversible one based on the cumulative dose received.The incidence of onset and the severity of the neuropathy increase as the number of cycles increase as does the prevalence of the toxicity. Gabapentin (Neurontin) and carbamazepine (Tegretol) are two drugs used in the treatment of autonomic dysfunction and peripheral neuropathic pain. Given the similar syndromes, a trial was first conducted to see if the use of these agents could prevent the progression of this oxaliplatin-associated toxicity. A second trial was then begun to see if these agents could totally prevent oxaliplatin-associated neurotoxicity. Methods: 34 consecutive patients receiving oxaliplatin-5-FU-leukovorin rescue chemotherapy for stage IV colon cancer were available for study. Treatment was determined by random drawing of treatment options. Results: In the intial study of 24 patients, grade 1 toxicity had to be reported before treatment was intiated with either drug, usually after the 2nd cycle. Treatment was begun a week before the 3rd cycle. Gabapentin was begun at 900 mg/day and escalated to 2700 mg/day, as needed. Carbamazepine was begun at 400 mg/day and escalated to 800 mg/day, as needed. A success rate for preventing any grade 3 or higher sensory symptomatology occurred in 75% (9/12) in both groups. No life-threatening nor persistent neuropathy occurred. To judge whether these agents could totally prevent the sensory neuropathy, the next 10 patients have been randomized at the start of their treatment to either gabapentin, carbamazepine or nothing. After 3 cycles the 6 treated patients have grade 1 sensory neuropathy while 2 of the 4 non-prophylaxed patients had grade 2 sensory neuropathy and were started on therapy before cycle 3. No drug toxicity associated with either carbamazepine or gabapentin was observed. Conclusions: While a prospective, double-blinded randomized trial needs to confirm these findings, gabapentin or carbamazepine can be considered as adjuvant therapy to minimize the sensory neuropathic toxicity of oxaliplatin. No significant financial relationships to disclose.
T cell–intrinsic ASC critically promotes TH17-mediated experimental autoimmune encephalomyelitis
Authors: Bradley N Martin, Chenhui Wang, Cun-jin Zhang, Zizhen Kang, Muhammet Fatih Gulen, Jarod A Zepp, Junjie Zhao, Guanglin Bian, Jeong-su Do, Booki Min, Paul G Pavicic, Caroline El-Sanadi, Paul L Fox, Aoi Akitsu, Yoichiro Iwakura, Anasuya Sarkar, Mark D Wewers, William J Kaiser, Edward S Mocarski, Marc E Rothenberg, Amy G Hise, George R Dubyak, Richard M Ransohoff, Xiaoxia Li
Journal: Nature Immunology (2016)
Phase 1B Study of Mehd7945A (Mehd) Plus Cisplatin/Fluorouracil (Cis/5Fu) or Carboplatin/Paclitaxel (Carbo/Pac) for 1St-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (Rmscchn)
Authors: P.M. Clement, J. Machiels, L.J. Wirth, P. Specenier, T. Seiwert, F. Mardjuadi, X. Wang, A. Kapp, S. Royer-Joo, E. Penuel, B. McCall, A. Pirzkall, A. Jimeno
Journal: Annals of Oncology (2014)
Melatonin-Induced Nocturnal Vasodilatation Contributes to Skin Regeneration–Reply
Authors: Yung-Sen Chang, Bor-Luen Chiang
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Severe Illness Associated with Reported Use of Synthetic Cannabinoids — Mississippi, April 2015
Authors: Amelia M. Kasper, Alison D. Ridpath, Justin K. Arnold, Kevin Chatham-Stephens, Melissa Morrison, Olaniyi Olayinka, Christina Parker, Robert Galli, Robert Cox, Nykiconia Preacely, Jannifer Anderson, Patrick B. Kyle, Roy Gerona, Colleen Martin, Josh Schier, Amy Wolkin, Thomas Dobbs
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

On April 2, 2015, four patients were evaluated at the University of Mississippi Medical Center (UMMC) in Jackson, Mississippi, for agitated delirium after using synthetic cannabinoids. Over the next 3 days, 24 additional persons went to UMMC with illnesses suspected to be related to synthetic cannabinoid use; one patient died. UMMC notified the Mississippi State Department of Health, which issued a statewide alert via the Health Alert Network on April 5, requesting that health care providers report suspected cases of synthetic cannabinoid intoxication to the Mississippi Poison Control Center (MPCC). A suspected case was defined as the occurrence of at least two of the following symptoms: sweating, severe agitation, or psychosis in a person with known or suspected synthetic cannabinoid use. A second statewide alert was issued on April 13, instructing all Mississippi emergency departments to submit line lists of suspected patients to MPCC each day. By April 21, 16 days after the first alert was issued, MPCC had received reports of approximately 400 cases, including eight deaths possibly linked to synthetic cannabinoid use; in contrast, during April 2012–March 2015, the median number of telephone calls to MPCC regarding synthetic cannabinoid use was one per month (range = 0–11). The Mississippi State Department of Health, with the assistance of CDC, initiated an investigation to better characterize the outbreak, identify risk factors associated with severe illness, and prevent additional illnesses and deaths.
Immunologic Studies in Chronic Lymphocytic Leukemia: Defective Stimulation of T-Cell Proliferation in Autologous Mixed Lymphocyte Culture2
Authors: J. Bruce Smith, Regina P. Knowlton, Lawrence S. Koons
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Immunologic Studies in Chronic Lymphocytic Leukemia: Defective Stimulation of T-Cell Proliferation in Autologous Mixed Lymphocyte Culture Get access J. Bruce Smith, J. Bruce Smith Search for other works by this author on: Oxford Academic PubMed Google Scholar Regina P. Knowlton, Regina P. Knowlton Search for other works by this author on: Oxford Academic PubMed Google Scholar Lawrence S. Koons Lawrence S. Koons Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 3, March 1977, Pages 579–585, https://doi.org/10.1093/jnci/58.3.579 Published: 01 March 1977 Article history Received: 25 June 1976 Accepted: 15 September 1976 Published: 01 March 1977
Symptomatic HIV infection of the CNS in a patient without clinical evidence of immune deficiency
Authors: A Beckett, P Summergrad, T Manschreck, H Vitagliano, M Henderson, M L Buttolph, M Jenike
Journal: American Journal of Psychiatry (1987)

Major depression with psychotic features, dementia, and focal neurologic abnormalities appeared in a Haitian man without AIDS or other syndromes of immune compromise. Neurologic evaluation, including brain biopsy, was nondiagnostic, but CSF culture revealed human immunodeficiency virus (HIV).
Potential Association Between Atrial Fibrillation and Dementia
Authors: Chan Chen, Jin Liu, Tao Zhu
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
New Appliances
Authors: S CARNE
Journal: BMJ (1964)

Any Questions?MENL JOURNLu animals have been noted by Treon et al.' Propyl ethylene has similar toxic properties.The effects in man were first described byHarris.! After a latent period of a few hours there is usually a sense of discomfort in the chest and a dry cough.A gradual increase in temperature, pulse rate, and respiration rate, followed by shivering and sweating are characteristic.Because the symptoms closely resemble those of " metalfume fever," Harris has termed the malady
Multigene Assays in Metastatic Colorectal Cancer
Authors: Kristin K. Deeb, Jakub P. Sram, Hanlin Gao, Marwan G. Fakih
Journal: Journal of the National Comprehensive Cancer Network (2013)

Specific genomic colorectal cancer alterations are increasingly linked to prognosis and/or response to specific anticancer agents. The identification of KRAS mutations as markers of resistance to epidermal growth factor receptor (EGFR) inhibitors has paved the way to the interrogation of numerous other markers of resistance to anti-EGFR therapy, such as NRAS, BRAF, and PI3KCA mutations. Other genomic and protein expression alterations have recently been identified as potential targets of treatment or as markers of chemotherapy or targeted-therapy resistance, including ERCC1 expression, c-Met expression, PTEN expression, HER2 amplification, HER3 expression, and rare KRAS mutations. As the number of distinct validated intratumor genomic assays increases, numerous molecular assays will need to be compiled into one multigene panel assay. Several companies and academic centers are now offering multigene assays to patients with metastatic colorectal cancer and other solid tumors. This article discusses the technology behind multigene assays, its limitations, its current advantages, and its potential in the clinical care of metastatic colorectal cancer.
Is It Time to Make Mind-Body Approaches Available for Chronic Low Back Pain?
Authors: Madhav Goyal, Jennifer A. Haythornthwaite
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal